Predictive Oncology reports positive results using AI for drug repurposing

Predictive Oncology (POAI) provided an update highlighting new successes with its drug repurposing initiative. Using publicly available datasets on drugs that have either been abandoned or discontinued by large pharmaceutical companies, Predictive Oncology has developed a registry of promising candidates that can potentially be repurposed for additional or alternative indications. By utilizing its proprietary AI and machine learning platform and leveraging its biobank of primary tumor samples and decades of drug response data, Predictive identified select drug candidates with promising mechanisms of action for further clinical testing with an initial focus on ovarian, colon and breast cancer and subsequently identified candidates with potential efficacy in treating colon and ovarian cancer. Predictive is also using its AI platform to identify a set of FDA-approved drugs for other cancers that show promising activity in ovarian cancer, the results of which will soon be made public. Utilizing its AI platform, the company believes that the ability to repurpose approved or abandoned drugs for additional indications represents a meaningful opportunity to deliver value by developing new therapies faster and cheaper than through traditional early drug discovery.